ストックスクリーナーアプリを入手
17.40
0.60%
-0.09
前日終値:
$17.49
開ける：
$17.36
24時間の取引高:
419.92K
Relative Volume:
0.15
時価総額：
$12.96B
収益：
$220.00K
当期純損益:
$-746.08M
株価収益率:
-17.27
EPS:
-1.0074
ネットキャッシュフロー:
$-211.81M
1週間 パフォーマンス:
-5.41%
1か月 パフォーマンス:
-2.82%
6か月 パフォーマンス:
-18.30%
1年 パフォーマンス:
-2.58%
1日の値動き範囲:
$17.15
$17.47
1週間の範囲:
$17.15
$18.36
52週間の値動き範囲:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.41 | 13.02B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.29 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.41 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.86 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.22 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.90 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Underweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Neutral |
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Farther Finance Advisors LLC Makes New $1.14 Million Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Capricorn Fund Managers Ltd Takes $10.25 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Closing the Year With Gratitude and Shared Purpose – Summit Therapeutics - Oncodaily
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Summit Therapeutics Inc. stock a defensive play in 20252025 Price Momentum & Free Community Consensus Stock Picks - Улправда
How Summit Therapeutics Inc. stock compares to industry benchmarks2025 Big Picture & Long Hold Capital Preservation Plans - ulpravda.ru
Will Summit Therapeutics Inc. stock outperform Dow Jones indexPortfolio Return Report & AI Powered Buy and Sell Recommendations - ulpravda.ru
How Summit Therapeutics Inc. stock valuations compare to rivalsJuly 2025 Opening Moves & Community Verified Trade Alerts - DonanımHaber
Can Summit Therapeutics Inc. stock continue upward trendJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Gap Down: How Summit Therapeutics Inc. stock valuations compare to rivalsWeekly Market Summary & Low Risk Profit Maximizing Plans - DonanımHaber
Gains Recap: Will Summit Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда
Barclays Upgrades Summit Therapeutics (SMMT) - Nasdaq
Barclays Upgrades SMMT, Raises Price Target to $18 | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Barclays to Equal Weight Rating - MarketBeat
Summit Therapeutics stock rating upgraded by Barclays on BLA timeline - Investing.com UK
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Trading Systems Reacting to (SMMT) Volatility - news.stocktradersdaily.com
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance
Citi asserts buy rating on Summit Therapeutics Inc. (SMMT) on pipeline development - MSN
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing? - Yahoo Finance
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
U.S. Markets Ended Tuesday Mixed As Galaxy Digital Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - ts2.tech
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.4%Here's Why - MarketBeat
Norges Bank Invests $29.58 Million in Summit Therapeutics PLC $SMMT - MarketBeat
New York State Common Retirement Fund Buys 227,513 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Schroder Investment Management Group Sells 89,090 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
State Board of Administration of Florida Retirement System Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - The Motley Fool
Why analysts upgrade Summit Therapeutics Inc. stockJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Summit Therapeutics Inc. (SMMT) Options Chain - Yahoo! Finance Canada
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - AOL.com
Summit Therapeutics (NASDAQ:SMMT) Trading 9.2% HigherShould You Buy? - MarketBeat
Can Summit Therapeutics Inc. stock maintain operating marginsWeekly Gains Report & AI Powered Market Trend Analysis - Newser
Don't Buy Summit Therapeutics Until This Big Thing Happen - Nasdaq
Widening Q3 Losses and Insider Buying Might Change The Case For Investing In Summit Therapeutics (SMMT) - Yahoo Finance
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
SMMT: Four positive phase 3 trials and accelerated timelines position the pipeline for NSCLC market leadership - TradingView
XTX Topco Ltd Makes New $925,000 Investment in Summit Therapeutics PLC $SMMT - MarketBeat
2 Monster Stocks in the Making to Buy and Hold - The Globe and Mail
Summit Therapeutics: InvestingPro’s Fair Value model predicted 37% downside By Investing.com - Investing.com Nigeria
Summit Therapeutics (SMMT) Stock Analysis Report | Financials & Insights - Benzinga
33,096 Shares in Summit Therapeutics PLC $SMMT Acquired by Inceptionr LLC - MarketBeat
Rhenman & Partners Asset Management AB Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
Summit Therapeutics Inc (SMMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.27%
0.57%
大文字化:
|
ボリューム (24 時間):